Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICPIs) are indicated as treatment for metastatic renal cell carcinoma (RCC) and melanoma, among other malignancies. This group of agents is associated with immune-related adverse events (irAEs). We aimed to further investigate the association of immune-related thyroid disorders (irTDs) with clinical outcomes and mortality rates in patients with RCC or melanoma who were treated with ICPIs.Methods: We retrospective...

Introduction: Immune check-point inhibitors (ICI) can cause adverse events in many organs due to the activation of T-cells. Data on the effect of ICI on bones and incidence of fracture is still scarce.Aim: To quantify the rate of osteoporotic fracture before and after the use of ICI in cancer patients.Methods: We retrospectively retrieved pertinent data of all patients who were treated with ICI between 2015 and 2023 at the Tel-Aviv...